Thrombosis News and Research

Latest Thrombosis News and Research

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS(R) Express(TM) Paclitaxel-Eluting Stent System.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER® Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor® Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

16 Mar 2010

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Physicians placing inferior vena cava (IVC) filters to prevent life-threatening pulmonary emboli now have access to the latest iteration of Cook Medical’s advanced NavAlign™ delivery system, a deployment system designed to minimize the risk of vessel trauma and streamline filter placement.

15 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Positive results from second phase of ABSORB clinical trial on BVS technology

Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

Hamilton Health Sciences establishes new research facility

Hamilton's role as one of the world's leading centres in cardiac, vascular and stroke research was amplified today with the grand opening of the David Braley Cardiac, Vascular and Stroke Research Institute at the Hamilton General Hospital site of Hamilton Health Sciences.

12 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

People with varicose veins should seek professional consultation

March is DVT Awareness Month and Vein Clinics of America encourages people with varicose veins, particularly those that have become painful and inflamed, to visit a vein specialist.

11 Mar 2010

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology.

11 Mar 2010

Combating DVT and PE: Critical recommendations

Three critical recommendations from a national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary embolism (PE), a growing public health problem estimated to affect nearly 1 million Americans each year.

10 Mar 2010

Varicose veins may signal potential dangerous blood clots

March is DVT Awareness Month and Vein Clinics of America encourages people with varicose veins, particularly those that have become painful and inflamed, to visit a vein specialist.

5 Mar 2010

LEO Pharma gains access to Intomics’ biological data analysis expertises

Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery.

5 Mar 2010

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.

5 Mar 2010

DVT Awareness In Motion: Educational program on the importance of preventative care for DVT

The Coalition to Prevent Deep-Vein Thrombosis moves into action with the seventh national DVT Awareness Month by introducing DVT Awareness In Motion, a educational program designed to drive dialogue about the importance of preventative care for DVT via simple movements – that can be done anywhere and anytime.

4 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Thrombosis News and Research

Latest Thrombosis News and Research

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Regado Biosciences announces first successful subcutaneous application of an aptamer

Positive results from second phase of ABSORB clinical trial on BVS technology

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Hamilton Health Sciences establishes new research facility

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

People with varicose veins should seek professional consultation

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

Combating DVT and PE: Critical recommendations

Varicose veins may signal potential dangerous blood clots

LEO Pharma gains access to Intomics’ biological data analysis expertises

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

DVT Awareness In Motion: Educational program on the importance of preventative care for DVT

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in